Drug eluting stent market seen reaching $11.7B by 2030

The global drug eluting stent market is projected to rise from $8.94 billion in 2026 to $11.7 billion by 2030, driven by rising coronary artery disease, more PCI procedures and growing demand for minimally invasive cardiac care. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Drug eluting stents are a core treatment for blocked coronary arteries and help reduce restenosis after PCI and angioplasty. - Rising cardiovascular disease burden is expanding demand for advanced stent technologies worldwide. - The market outlook points to continued investment in minimally invasive cardiac care, specialized centers and new stent designs.

What happened: - The Business Research Company published its Drug Eluting Stent Global Market Report 2026, covering market size, trends and forecast data through 2035. - The report estimates the market will grow from $8.26 billion in 2025 to $8.94 billion in 2026, an 8.2% CAGR. - The market is projected to reach $11.7 billion by 2030, with a 6.9% CAGR. - The report includes regional analysis for Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company offers a free sample report and the full market report.

The details: - A drug-eluting stent is a small mesh-like metallic tube inserted into narrowed or blocked coronary arteries during PCI or angioplasty. - The device supports the artery and releases medication to help prevent the artery from narrowing again. - Historic growth in the market has been driven by rising coronary artery disease, more PCI procedures, more lifestyle-related cardiovascular disorders, a growing number of cardiac catheterization laboratories and better clinical outcomes than bare-metal stents. - Future growth drivers include an aging global population, higher demand for minimally invasive cardiac treatments, greater patient awareness of advanced stent technologies, expansion of specialized cardiac care centers and higher healthcare spending on cardiovascular disease management. - Expected trends include wider adoption of biodegradable polymer stents, preference for polymer-free drug-eluting stents, expanded use in complex coronary procedures, stronger focus on long-term restenosis prevention and improved drug release control. - The report says the main market driver is the increasing prevalence of coronary heart disease, which narrows or blocks coronary arteries and can lead to heart attacks or chest pain. - A National Center for Biotechnology Information report released in August 2025 projects a 90% increase in cardiovascular disease prevalence between 2025 and 2050, along with a 73.4% rise in crude mortality and a 54.7% increase in disability-adjusted life years. - The same report projects cardiovascular deaths will reach 35.6 million by 2050, up from 20.5 million in 2025.

Between the lines: - The forecast suggests the market is maturing, but still has room for steady expansion as cardiovascular disease rates climb and hospitals favor less invasive procedures. - Growth in biodegradable and polymer-free stents points to a push for lower complication risk and longer-term performance. - North America’s lead suggests a more established procedure base, while faster Asia-Pacific growth likely reflects broader access, rising spending and expanding cardiac care infrastructure.

What's next: - The report expects the market to keep growing through 2030 and beyond as the global burden of heart disease increases. - Product innovation is likely to stay focused on drug delivery control, restenosis prevention and complex coronary applications. - Regional competition may intensify as Asia-Pacific expands and more cardiac centers adopt advanced stent technologies. - The company says its 2026 reports also add market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards and market hotspot infographics.

The bottom line: - Drug eluting stents remain a growing cardiovascular device market, supported by rising disease prevalence, procedural volume and a shift toward minimally invasive treatment options.